Using galleria mellonella-candida albicans infection model to evaluate antifungal agents

Biological and Pharmaceutical Bulletin

Volumn 36, Issue 9, 2013, Pages 1482-1487

  Li, De Dong ^a   Deng, Li ^a   Hu, Gan Hai ^a,b   Zhao, Lan Xue ^a,b   Hu, Dan Dan ^a   Jiang, Yuan Ying ^a   Wang, Yan ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b FUJIAN UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

Antifungal agent; Candida albicans; Galleria mellonella

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; FLUCONAZOLE; FLUCYTOSINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDA ALBICANS; CANDIDIASIS; COLONY FORMING UNIT; CONTROLLED STUDY; DISEASE MODEL; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG POTENTIATION; DRUG SCREENING; GALLERIA MELLONELLA; IN VIVO STUDY; INOCULATION; MONOTHERAPY; NONHUMAN; TREATMENT OUTCOME;

AMPHOTERICIN B; ANIMALS; ANTIFUNGAL AGENTS; CANDIDA ALBICANS; DISEASE MODELS, ANIMAL; FLUCONAZOLE; FLUCYTOSINE; LARVA; MOTHS;

EID: 84884633178     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.b13-00270     Document Type: Article

References (27)

1. Fidel PL Jr. Candida-host interactions in HIV disease: implications for oropharyngeal candidiasis. Adv. Dent. Res., 23, 45-49 (2011).
2. Ascioglu S, Rex JH, de Pauw B, Bennett JE, Bille J, Crokaert F, Denning DW, Donnelly JP, Edwards JE, Erjavec Z, Fiere D, Lortholary O, Maertens J, Meis JF, Patterson TF, Ritter J, Selleslag D, Shah PM, Stevens DA, Walsh TJ. Invasive Fungal Infections Cooperative Group of the European Organization for Research and Treatment of Cancer Mycoses Study Group of the National Institute of Allergy and Infectious Diseases. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin. Infect. Dis., 34, 7-14 (2002).
3. Benjamin DK Jr, Garges H, Steinbach WJ. Candida bloodstream infection in neonates. Semin. Perinatol., 27, 375-383 (2003).
4. Alexander BD, Perfect JR. Antifungal resistance trends towards the year 2000. Implications for therapy and new approaches. Drugs, 54, 657-678 (1997).
5. Moudgal V, Sobel J. Antifungals to treat Candida albicans. Expert Opin. Pharmacother., 11, 2037-2048 (2010).
6. Vilcinskas A. Insects emerge as valuable model hosts to explore virulence. Virulence, 2, 376-378 (2011).
7. Mylonakis E, Casadevall A, Ausubel FM. Exploiting amoeboid and non-vertebrate animal model systems to study the virulence of human pathogenic fungi. PLoS Pathog., 3, e101 (2007).
8. Desalermos A, Fuchs BB, Mylonakis E. Selecting an invertebrate model host for the study of fungal pathogenesis. PLoS Pathog., 8, e1002451 (2012).
9. Brennan M, Thomas DY, Whiteway M, Kavanagh K. Correlation between virulence of Candida albicans mutants in mice and Galleria mellonella larvae. FEMS Immunol. Med. Microbiol., 34, 153-157 (2002).
10. Junqueira JC. Galleria mellonella as a model host for human pathogens: recent studies and new perspectives. Virulence, 3, 474-476 (2012).
11. Fuchs BB, O'Brien E, Khoury JB, Mylonakis E. Methods for using Galleria mellonella as a model host to study fungal pathogenesis. Virulence, 1, 475-482 (2010).
12. Fallon JP, Troy N, Kavanagh K. Pre-exposure of Galleria mellonella larvae to different doses of Aspergillus fumigatus conidia causes differential activation of cellular and humoral immune responses. Virulence, 2, 413-421 (2011).
13. Aperis G, Fuchs BB, Anderson CA, Warner JE, Calderwood SB, Mylonakis E. Galleria mellonella as a model host to study infection by the Francisella tularensis live vaccine strain. Microbes Infect., 9, 729-734 (2007).
14. Mylonakis E, Moreno R, El Khoury JB, Idnurm A, Heitman J, Calderwood SB, Ausubel FM, Diener A. Galleria mellonella as a model system to study Cryptococcus neoformans pathogenesis. Infect. Immun., 73, 3842-3850 (2005).
15. Peleg AY, Jara S, Monga D, Eliopoulos GM, Moellering RC Jr, Mylonakis E. Galleria mellonella as a model system to study Acinetobacter baumannii pathogenesis and therapeutics. Antimicrob. Agents Chemother., 53, 2605-2609 (2009).
16. Fallon J, Kelly J, Kavanagh K. Galleria mellonella as a model for fungal pathogenicity testing. Methods Mol. Biol., 845, 469-485 (2012).
17. Lüttich A, Brunke S, Hube B, Jacobsen ID. Serial passaging of Candida albicans in systemic murine infection suggests that the wild type strain SC5314 is well adapted to the murine kidney. PLoS ONE, 8, e64482 (2013).
18. Rymovicz AU, Souza RD, Gursky LC, Rosa RT, Trevilatto PC, Groppo FC, Rosa EA. Screening of reducing agents for anaerobic growth of Candida albicans SC5314. J. Microbiol. Methods, 84, 461-466 (2011).
19. El-Sheekh MM, Mahmoud YA, Abo-Shady AM, Hamza W. Efficacy of Rhodotorula glutinis and Spirulina platensis carotenoids in immunopotentiation of mice infected with Candida albicans SC5314 and Pseudomonas aeruginosa 35. Folia Microbiol. (Praha), 55, 61-67 (2010).
20. Wong PN, Lo KY, Tong GM, Chan SF, Lo MW, Mak SK, Wong AK. Treatment of fungal peritonitis with a combination of intravenous amphotericin B and oral flucytosine, and delayed catheter replacement in continuous ambulatory peritoneal dialysis. Perit. Dial. Int., 28, 155-162 (2008).
21. Pappas PG, Rex JH, Sobel JD, Filler SG, Dismukes WE, Walsh TJ, Edwards JE; Infectious Diseases Society of America. Guidelines for treatment of candidiasis. Clin. Infect. Dis., 38, 161-189 (2004).
22. Cowen LE, Singh SD, Köhler JR, Collins C, Zaas AK, Schell WA, Aziz H, Mylonakis E, Perfect JR, Whitesell L, Lindquist S. Harnessing Hsp90 function as a powerful, broadly effective therapeutic strategy for fungal infectious disease. Proc. Natl. Acad. Sci. U.S.A., 106, 2818-2823 (2009).
23. McCann M, Curran R, Ben-Shoshan M, McKee V, Tahir AA, Devereux M, Kavanagh K, Creaven BS, Kellett A. Silver(I) complexes of 9-anthracenecarboxylic acid and imidazoles: synthesis, structure and antimicrobial activity. Dalton Trans., 41, 6516-6527 (2012).
24. Pappas PG, Kauffman CA, Andes D, Benjamin DK Jr, Calandra TF, Edwards JE Jr, Filler SG, Fisher JF, Kullberg BJ, Ostrosky-Zeichner L, Reboli AC, Rex JH, Walsh TJ, Sobel JD; Infectious Diseases Society of America. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin. Infect. Dis., 48, 503-535 (2009).
25. Hanaoka N, Takano Y, Shibuya K, Fugo H, Uehara Y, Niimi M. Identification of the putative protein phosphatase gene PTC1 as a virulence-related gene using a silkworm model of Candida albicans infection. Eukaryot. Cell, 7, 1640-1648 (2008).
26. Arvanitis M, Glavis-Bloom J, Mylonakis E. Invertebrate models of fungal infection. Biochim. Biophys. Acta, 1832, 1378-1383 (2013).
27. Arakawa T, Kita Y, Timasheff SN. Protein precipitation and denaturation by dimethyl sulfoxide. Biophys. Chem., 131, 62-70 (2007).